alexa The Vaxonella Platform For Oral Recombinant Vaccine Delivery
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Rocky M Cranenburgh
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.020
Abstract
V axonella? achieves targeted mucosal delivery of plasmid-expressed vaccines via the lining of the small intestine. It uses the live attenuated Salmonella enterica serovar Typhi strain ZH9 and associated genetic and formulation technologies. The ZH9 vector is very safe with attenuating mutations in genes for chrosimate synthase ( aroC ) and the type III secretion system ( ssaV ), and has been administered to over 400 volunteers in seven clinical trials (Phase I and II). It generates strong systemic and mucosal immune responses, making adjuvants unnecessary. Vaxonella features X-mark?, a technology that enables plasmids to be constructed using standard antibiotic selection in an Xer mutant strain of E. coli. These undergo automatic antibiotic resistance gene deletion by Xer recombination once transformed into any other enteric bacterium. The removal of the constitutively expressed selectable marker gene greatly reduces the major component of the metabolic burden which leads to plasmid loss. For further stability ORT-VAC? is used: the only mechanism that enables maintenance of any enteric plasmid in the absence of an expressed selectable marker gene. A capsule formulation incorporating a bile-adsorbing resin protects dried Salmonella from the detrimental effects of bile until their natural resistance is restored by rehydration. Vaxonella? has been used to develop Typhetec?, a dual oral vaccine against typhoid and diarrhoea due to ETEC (Enterotoxigenic Escherichia coli ). ETEC is the most common cause of diarrhoea amongst travellers yet there is no dedicated ETEC vaccine available. We are additionally developing a new oral vaccine against Clostridium difficile , a major cause of nosocomial infections.
Biography
Rocky M Cranenburgh is the CSO of Prokarium, a biotechnology company specialising in oral vaccine development and delivery. He completed a PhD in Genomics of Cyanobacteria at Newcastle University in 1997 and joined Cobra Biologics in Staffordshire later that year, a position which included a placement at the University of Oxford (1998-99). He led Cobra?s Molecular Biology Group from 2000, which conducted numerous internal R&D projects and contracts for biopharmaceutical companies in the field of recombinant protein and DNA production. He was involved in spinning Prokarium out from Cobra in 2012, and has developed several new genetic technologies and vaccine candidates
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords